MedTrace Logo

Thromboelastography to Study Burn Coagulopathy

NCT06879509 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-03-17

No results posted yet for this study

Summary

This pilot study examines the use of thromboelastography (TEG), a specialized blood test, to evaluate clotting abnormalities in burn patients. The study aims to understand how burn injuries impact the body's ability to form and break down blood clots over time. Specifically, the investigators will research whether the percentage of total body surface area burned (%TBSA) is associated with changes in blood clotting, track the evolution of clotting patterns during the first four weeks following a burn injury, and explore whether these changes can predict recovery or complications. By providing new insights into clotting dynamics in burn patients, the study seeks to improve diagnostic methods, enhance monitoring strategies, and guide treatments to optimize patient care and outcomes.

Conditions

  • Burn
  • Coagulation, Blood

Interventions

DIAGNOSTIC_TEST

Thromboelastography

All participants will receive this intervention. Thromboelastography (TEG) is a blood test that provides a detailed assessment of the clotting process, measuring how blood clots form, strengthen, and dissolve. It offers real-time insights into a patient's coagulation status, helping to identify clotting disorders and guide treatment decisions.

Sponsors & Collaborators

  • Francesco Egro

    lead OTHER

Principal Investigators

  • Francesco M Egro, MD, MSc, MRCS · Department of Plastic Surgery, University of Pittsburgh Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2025-08-31
Completion
2025-08-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06879509 on ClinicalTrials.gov